In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Sets New Biotech M&A Record

Executive Summary

Pfizer's proposed acquisition of Rinat Neuroscience is the costliest private biotech purchase yet--it paid $500 million in cash for the CNS play. What's more extraordinary still is that the most valuable asset at Rinat is pre-clinical.

Related Content

With Twists And Turns, KaloBios Goes Public
Where Are They Now? Checking In With Four Alzheimer’s Disease Start-Ups
Alzheimer's R&D: Tweaking Venture's Risk-Reward Ratio
Reformulation has Ruled in Neurology Dealmaking--Until Now
Pharmaceutical Strategic Alliances 2006: Forcing Externalization at Big Pharma
Auctions: Getting the Best Value for Your Asset
Trade Sales Trump IPOs, Even for Platforms
Stepping Out, Not Up: Better Returns for VCs Through M&A?
Pfizer's Analyst Day: And Now, For Its Next Trick
Pfizer's Analyst Day: And Now, For Its Next Trick


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts